Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Clinical trial NCT06487078 · RECRUITING

Trial details

NCT number: NCT06487078
Sponsor: Pfizer
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

ALK+ Non-Small-Cell Lung Carcinoma

Start date: 2025-01-20
Primary completion: 2028-11-30
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.